Navigation Links
Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)

SEATTLE, Sept. 24 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTAX: CTIC) today announced that Richard L. Love has joined its board of directors. Love was the Chairman of the Board for Systems Medicine, which was recently acquired by CTI. Systems Medicine, which works with the Translation Genomics Institute ("TGen") in Arizona, uses the latest drug development technology to discover weak spots in a disease's genetic make-up and identify which drugs will be most effective at treating the disease.

James A. Bianco, M.D., President and CEO of CTI said, "Dick brings a wealth of entrepreneurial and drug development experience in the biopharmaceutical industry to CTI's board. We look forward to his input as we move toward the commercialization of pixantrone, XYOTAX(TM), and Brostallicin."

Love has worked in the industry for more than 40 years, including 27 years of bioscience leadership experience. He founded two biopharmaceutical companies, Triton Biosciences Inc. and ILEX Oncology, Inc. Love was CEO at both companies, and leading the clinical development teams in the creation of four drugs currently in use -- Betaseron(R), a treatment for multiple sclerosis, two treatments for chronic lymphocytic leukemia, Fludara(R) and CAMPATH(R), and Clolar(R), a treatment for acute leukemias.

"We are very excited to have Dick join CTI's board, and look forward to utilizing his industry expertise," said Phillip M. Nudelman, Ph.D., Chairman of the Board of CTI. "His leadership experience makes him a great addition to the board."

In addition to CTI, Love is currently Chairman of the Board of ImaRx Therapeutics, and he serves on the boards of PAREXEL International, and Molecular Profiling Institute. He previously served on the board of Xilas Medical, Inc. Love has been active with various non-profit organizations as well, serving on the boards of the Cancer Therapy and Research Center (CTRC) in San Antonio, TX, and the Translation Genomics Research Institute (TGen) in Phoenix, AZ.

"I am thrilled to join the CTI board and to have the opportunity to help the company reach its goal of making cancer more treatable," said Love. "I am fully committed to the Company's mission and look forward to contributing my experience to the development of both the Company and its drug candidates."

Mr. Love holds Bachelors and Masters of Science degrees in Chemical Engineering from the Virginia Polytechnic Institute.

In addition to Love, CTI's Board of Directors includes Phillip M. Nudelman, Ph.D., Chairman of the Board, President and Chief Executive of The Hope Heart Institute and former President and CEO of Group Health Cooperative; Frederick W. Telling, Ph.D., former Corporate Officer and Vice President of Corporate Policy and Strategic Management for Pfizer Inc.; Vartan Gregorian, Ph.D., President of Carnegie Corporation of New York; Mary O. Mundinger, Dr. PH, Dean and Professor, School of Nursing and Associate Dean, Faculty of Medicine, Columbia University; John H. Bauer, former EVP of Finance for Nintendo of America, Inc.; James A. Bianco, M.D., President and CEO of CTI; and Jack W. Singer, M.D., Chief Medical Officer of CTI.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit

Media Contact:

Dan Eramian

T: 206.272.4343

C: 206.854.1200

Susan Callahan

T: 206.272.4472

F: 206.272.4434

Lindsey Jesch

T: 206.272.4347


Investors Contact:

Leah Grant

T: 206.282.7100

F: 206.272.4434


SOURCE Cell Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Leadership insights from co-founder of Yesmail
2. John Bergman, co-founder of Guild Software
3. At Berbee, president replaces founder as CEO
4. Online Kiosks founder Mike Strand uses contest to screen new business plan
5. Third Wave co-founder shoots for small target in latest project
6. Entrepreneurial Profile: Kelly Henrickson, founder of Prodesse, Inc.
7. Strandware Founder Establishes Consulting Firm
8. Epics Founder Judy Faulkner Speaks on Culture, Business Beliefs, and Recruiting: WTN Exclusive Coverage
9. Interview: Billpoint Founder Jason May on eBay, Open Source
10. WTN Interview: Alex Bratton: EmailRXs founder on viruses and spam
11. ESR1 Gene Expression in Oncology and Metabolic Diseases Using the ASCENTATM System Target Validation and Identification of Novel Disease Indications
Post Your Comments:
(Date:11/25/2015)...  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced ... of Neurocrine Biosciences, will be presenting at the 27th ... York . .   ... minutes prior to the presentation to download or install ... be available on the website approximately one hour after ...
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica Richman and Zachary ... in their initial angel funding process. Now, they are paying it forward to ... early stage investments in the microbiome space. In this, they join other ...
(Date:11/24/2015)... , Nov. 24, 2015 /CNW/ - iCo Therapeutics ("iCo" ... reported financial results for the quarter ended September ... in Canadian dollars and presented under International Financial ... States ," said Andrew Rae , ... regarding iCo-008 are not only value enriching for ...
(Date:11/24/2015)... , November 24, 2015 ... market research report "Oligonucleotide Synthesis Market by Product & ... Gene Synthesis, Diagnostic, DNA, RNAi), End-User (Research, Pharmaceutical & ... by MarketsandMarkets, the market is expected to reach USD ... 2015, at a CAGR of 10.1% during the forecast ...
Breaking Biology Technology:
(Date:11/11/2015)... --  MedNet Solutions , an innovative SaaS-based eClinical technology company ... to announce that it will be a Sponsor of the ... be held November 17-19 in Hamburg , ... iMedNet , MedNet,s easy-to-use, proven and affordable ... been able to deliver time and cost savings of up ...
(Date:11/4/2015)... New York , November 4, 2015 ... to a new market report published by Transparency Market ... Share, Growth, Trends and Forecast 2015 - 2022", the global ... of US$ 30.3 bn by 2022. The market is ... the forecast period from 2015 to 2022. Rising security ...
(Date:10/29/2015)... Oct. 29, 2015  Rubicon Genomics, Inc., today ... distribution of its DNA library preparation products, including ... new ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq has been ... of NGS libraries for liquid biopsies--the analysis of ... prognostic applications in cancer and other conditions. Eurofins ...
Breaking Biology News(10 mins):